Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.980
-0.120 (-2.35%)
At close: Mar 12, 2026, 4:00 PM EDT
5.03
+0.05 (1.02%)
After-hours: Mar 12, 2026, 4:20 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
364.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.42M |
| X4 Pharmaceuticals | 33.98M |
| Bicycle Therapeutics | 28.34M |
| LENZ Therapeutics | 17.50M |
| Absci | 2.82M |
| Neurogene | 925.00K |
CADL News
- 9 hours ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 days ago - Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 10 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - GlobeNewsWire
- 20 days ago - Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus - Benzinga
- 20 days ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 21 days ago - Candel Therapeutics Announces Proposed $100 Million Public Offering - GlobeNewsWire
- 21 days ago - Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire